Experts Push for Bolder Radiopharmaceutical Dosing — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Louise Emmett, a leader in the radiopharmaceuticals field who works with global drugmakers including AstraZeneca and Novartis, is urging developers to be bolder with dosing, arguing the industry is "scared of their power" to destroy cancer cells.
- Radiopharmaceuticals are described as a powerful new oncology tool — 21st-century spins on radiation that experts believe can destroy cancer cells and help patients live longer.
- Over the past five years, experimental radiopharmaceutical therapies have inadvertently affected patients' kidneys, liver, or bone marrow, creating safety concerns across the field.
- At least one company has shut down in recent months due to those safety issues, and other organizations have faced what the source describes as "headaches."
- Emmett and likeminded experts contend that radiopharmaceuticals can be dosed more frequently than current regimens call for — a position that runs directly against the recent cautious retreat by some developers.
Why it matters: The dosing debate pits oncologists like Emmett, who want to maximize radiopharmaceuticals' cancer-killing potential, against a drug industry that has already absorbed at least one company shutdown and organ-toxicity setbacks over the past five years — meaning the next round of clinical trial designs will directly determine how aggressively this promising class is deployed.
Ask SkimNews
